Morgan Stanley Reiterates Overweight Rating on Johnson & Johnson (JNJ)

Market Context

Johnson & Johnson operates in the Healthcare sector. The stock currently trades at $263.40 with a market capitalization of $505.8B. The stock has gained 40.9% over the past 52 weeks.

Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Johnson & Johnson.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Johnson & Johnson

Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 08, 2026	Citigroup	Buy	N/A
Jul 08, 2026	Morgan Stanley	Overweight	N/A
Jun 26, 2026	Guggenheim	Buy	N/A
May 13, 2026	Leerink Partners	Outperform	N/A
Apr 15, 2026	Wells Fargo	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View JNJ Stock Page